Cardiff Oncology director granted 40,565 stock options
Cardiff Oncology, Inc. director James O. Armitage was granted stock options covering 40,565 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Cardiff Oncology, Inc. director James O. Armitage was granted stock options covering 40,565 shares of common stock. The options have an exercise price of $1.59 per share and expire on June 11, 2036. After this award, he holds 228,104 derivative securities directly.
Insider Trade Summary
Grant/Award: 40,565 shares
Grant/Award
1 txn
Insider
Armitage James O
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options | 40,565 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options — 228,104 contracts (Direct)
Key Figures
Stock options granted: 40,565 options
Exercise price: $1.59 per share
Expiration date: June 11, 2036
+1 more
4 metrics
Stock options granted
40,565 options
Grant to director on June 11, 2026
Exercise price
$1.59 per share
Conversion or exercise price of options
Expiration date
June 11, 2036
Option term end for granted stock options
Derivative holdings after grant
228,104 securities
Total derivative securities held directly after transaction
Key Terms
Stock Options, Grant, award, or other acquisition, Common Stock, expiration date
4 terms
Stock Options financial
"security_title: "Stock Options""
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
Common Stock financial
"underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
expiration date financial
"expiration_date: "2036-06-11T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Cardiff Oncology (CRDF) report for James O. Armitage?
Cardiff Oncology director James O. Armitage received a grant of stock options for 40,565 shares of common stock. This was a compensation-related award, not an open-market purchase or sale, and increases his derivative holdings tied to the company’s stock.
What is the exercise price of the new Cardiff Oncology (CRDF) stock options?
The granted stock options have an exercise price of $1.59 per share. This is the price at which James O. Armitage can buy Cardiff Oncology common stock under the award during the option term, subject to any vesting conditions not detailed here.
When do James O. Armitage’s new Cardiff Oncology (CRDF) options expire?
The stock options granted to James O. Armitage expire on June 11, 2036. This long-dated expiration gives him a multi-year period to potentially exercise the options at $1.59 per share if conditions for exercise are met in the future.
How many Cardiff Oncology (CRDF) derivative securities does James O. Armitage hold after this grant?
Following the option grant, James O. Armitage holds 228,104 derivative securities. This figure reflects his direct derivative position, including the newly awarded 40,565 stock options linked to Cardiff Oncology common shares, as reported in the transaction details.
Was this Cardiff Oncology (CRDF) insider transaction a market buy or sell?
No, this was not a market buy or sell. The transaction is classified as a grant or award acquisition of stock options, meaning the director received options as compensation rather than trading Cardiff Oncology shares in the open market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates